To access this element change to forms mode OFF
Grant Award View - GA67176
An international, double-blind, dose increment, parallel-arm, randomised...
GA ID:
GA67176
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
12-Nov-2019
Publish Date:
20-Dec-2019
Category:
Health and Medical Research
Grant Term:
1-Jan-2020 to 31-Dec-2024
Value (AUD):
$978,610.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 18/19 1.1 Health and Medical Research
Grant Program:
Clinical Trials and Cohort Studies
Grant Activity:
An international, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid unresponsive cancer-related neuropathic pain: Phase III trial
Purpose:
Neuropathic pain (nerve pain) is a problem for many people with cancer and this pain is usually treated with pain-reliever drugs with the addition of antiseizure and/or antidepressant drugs. However, good quality research is low in determining if using antiseizure or antidepressant is more effective. Therefore, the purpose of this study is to investigate whether two medications, called duloxetine and pregabalin improves pain relief for adults with cancer who have neuropathic pain.
GO ID:
GO Title:
Clinical Trials and Cohort Studies 2019 Grant Opportunity
Internal Reference ID:
GNT1188023
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Technology Sydney
Recipient ABN:
77 257 686 961
Grant Recipient Location
Suburb:
Ultimo
Town/City:
Ultimo
Postcode:
2007
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT, NSW, VIC, SA, QLD
Postcode:
Multiple
Country:
AUSTRALIA